Kriya Therapeutics

Executive Summary

Kriya Therapeutics is a privately held biopharmaceutical company founded in 2019 and headquartered in Research Triangle Park, North Carolina. The company is pioneering the development of gene therapies for prevalent chronic diseases, aiming to expand the reach of gene therapy beyond ultra-rare conditions to millions of patients worldwide. By leveraging a proprietary platform that integrates vector engineering, capsid design, and manufacturing innovations, Kriya seeks to overcome the key challenges of durability, immunogenicity, and scalability that have historically limited gene therapy to niche indications. The company's pipeline targets large-market indications in metabolic, endocrine, and ocular diseases, with a focus on conditions such as type 2 diabetes, obesity, and wet age-related macular degeneration. As a private entity, Kriya has not disclosed detailed financial or clinical data, but its strategic emphasis on common diseases and its experienced leadership team position it as a potential disruptor in the gene therapy space. The company's progress will depend on its ability to advance candidates through preclinical and early clinical stages while securing the substantial capital required for gene therapy development.

Upcoming Catalysts (preview)

• TBDInitiation of first-in-human clinical trial for lead candidate40% success
• 2026Series C or later financing round to support pipeline expansion60% success
• TBDAnnouncement of strategic partnership with large pharma for manufacturing or platform access50% success